Trevi Therapeutics (TRVI) Income towards Parent Company (2018 - 2026)
Trevi Therapeutics (TRVI) recorded quarterly Income towards Parent Company of -$13.2 million in Q1 2026, down 58.63% quarter-over-quarter from -$8.3 million in Q4 2025, and down 27.58% on a YoY basis from -$18.2 million in Q1 2025.
Trevi Therapeutics (TRVI) Income towards Parent Company (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$13.2 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 27.58% year-over-year to -$13.2 million; the TTM figure through Mar 2026 stood at -$45.6 million (up 3.67% YoY), while the FY2025 annual figure was -$42.8 million, up 10.75% from the prior year.
- Income towards Parent Company was -$13.2 million for Q1 2026 at Trevi Therapeutics, down from -$8.3 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$5.5 million in Q4 2022 to a low of -$13.2 million in Q3 2024.
- Historically, Income towards Parent Company has averaged -$9.5 million across 5 years, with a median of -$8.3 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Income towards Parent Company soared 35.39% in 2022, then tumbled 72.88% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at -$5.5 million in 2022, then plunged by 42.07% to -$7.8 million in 2023, then slumped by 45.95% to -$11.4 million in 2024, then climbed by 27.15% to -$8.3 million in 2025, then slumped by 58.63% to -$13.2 million in 2026.
- The last three Income towards Parent Company figures came in at -$13.2 million (Q1 2026), -$8.3 million (Q4 2025), and -$11.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Trevi Therapeutics | 2.08 Bn | 1.91 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.19 Mn |
| Dec 31, 2025 | -8.32 Mn |
| Sep 30, 2025 | -11.80 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | -10.34 Mn |
| Dec 31, 2024 | -11.42 Mn |
| Sep 30, 2024 | -13.24 Mn |
| Jun 30, 2024 | -12.35 Mn |
| Mar 31, 2024 | -10.90 Mn |
| Dec 31, 2023 | -7.82 Mn |
| Sep 30, 2023 | -7.70 Mn |
| Jun 30, 2023 | -7.15 Mn |
| Mar 31, 2023 | -6.40 Mn |
| Dec 31, 2022 | -5.51 Mn |
| Sep 30, 2022 | -8.27 Mn |
| Jun 30, 2022 | -8.05 Mn |
| Mar 31, 2022 | -7.33 Mn |
| Dec 31, 2021 | -8.52 Mn |
| Sep 30, 2021 | -7.26 Mn |
| Jun 30, 2021 | -9.79 Mn |